dc.contributor.upauthor |
Rossouw, Theresa M.
|
|
dc.date.accessioned |
2008-06-02T13:17:25Z |
|
dc.date.available |
2008-06-02T13:17:25Z |
|
dc.date.issued |
2007-11 |
|
dc.description.abstract |
No abstract available |
en |
dc.format.extent |
93955 bytes |
|
dc.format.mimetype |
application/pdf |
|
dc.identifier.citation |
Rossouw, T 2007, 'Quantifying antiretroviral risk in pregnancy', South African Medical Journal, vol. 97, no. 11, pp. 1014-1015. [www.samj.org.za ] |
en |
dc.identifier.issn |
0038-3469 |
|
dc.identifier.uri |
http://hdl.handle.net/2263/5754 |
|
dc.language.iso |
en |
en |
dc.publisher |
Health and Medical Publishing Group |
en |
dc.rights |
Health and Medical Publishing Group |
en |
dc.subject |
Antiretroviral drugs |
en |
dc.subject |
Risk factors |
en |
dc.subject |
Risks |
en |
dc.subject |
Fetal outcome |
en |
dc.subject |
Efavirenz |
en |
dc.subject |
Pregnancy |
en |
dc.subject |
Neural tube defects |
en |
dc.subject |
Birth defects |
en |
dc.subject |
First trimester |
en |
dc.subject |
Highly active antiretroviral therapy (HAART) |
en |
dc.subject |
Viral loads |
en |
dc.subject |
Obstetric outcome |
en |
dc.subject |
Neonatal outcomes |
en |
dc.subject |
Statistics |
en |
dc.subject |
Treatment Outcome |
en |
dc.subject |
Gauteng |
en |
dc.subject.lcsh |
Pregnant women |
|
dc.subject.lcsh |
HIV-positive women |
|
dc.subject.lcsh |
Antiretroviral agents |
|
dc.subject.lcsh |
Fetus--Development |
|
dc.subject.lcsh |
Newborn infants |
|
dc.title |
Quantifying antiretroviral risk in pregnancy |
en |
dc.type |
Text |
en |